Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00299494 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
NCT00299494 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 119 participants.
The verdict
NCT00299494, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin \[CMC-544\] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL.
Interventions
- DRUG Rituximab
- DRUG inotuzumab ozogamicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2006-05-04 |
| Est. Completion | 2014-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00299494
The ClinicalTrials.gov registry entry for NCT00299494 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00299494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00299494 about?
NCT00299494 is a clinical study titled "Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)". The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin \[CMC-544\] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or m...
What is the current status of trial NCT00299494?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2006-05-04. Estimated completion is 2014-06-02.
What interventions are being tested in trial NCT00299494?
The interventions under investigation include: Rituximab (DRUG), inotuzumab ozogamicin (DRUG).
Who is sponsoring clinical trial NCT00299494?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.